Westside Investment Management Inc. Sells 43,453 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Westside Investment Management Inc. decreased its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 575,222 shares of the company’s stock after selling 43,453 shares during the period. Eton Pharmaceuticals makes up 1.6% of Westside Investment Management Inc.’s holdings, making the stock its 12th biggest position. Westside Investment Management Inc. owned 2.21% of Eton Pharmaceuticals worth $7,662,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Nantahala Capital Management LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth $3,095,000. Wasatch Advisors LP bought a new position in shares of Eton Pharmaceuticals in the third quarter worth $1,431,000. Aristides Capital LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth $658,000. Stonepine Capital Management LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth $362,000. Finally, Renaissance Technologies LLC boosted its stake in Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares in the last quarter. Institutional investors own 27.86% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ETON. Craig Hallum raised their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. B. Riley began coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, HC Wainwright raised their price objective on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, January 6th.

Eton Pharmaceuticals Trading Up 5.3 %

Shares of ETON stock opened at $15.18 on Wednesday. The business’s 50-day moving average price is $12.51 and its 200-day moving average price is $8.02. Eton Pharmaceuticals, Inc. has a 12 month low of $3.03 and a 12 month high of $15.71. The firm has a market capitalization of $395.39 million, a price-to-earnings ratio of -69.41 and a beta of 1.38.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.